A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)

被引:70
作者
Porter, Chad K. [1 ]
Riddle, Mark S. [1 ]
Tribble, David R. [2 ]
Bougeois, A. Louis [3 ]
McKenzie, Robin [3 ]
Isidean, Sandra D. [1 ]
Sebeny, Peter [4 ]
Savarino, Stephen J. [1 ]
机构
[1] USN, Med Res Ctr, Enter Dis Dept, Silver Spring, MD 20910 USA
[2] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Naval Med Res Unit 3, Cairo, Egypt
关键词
Enterotoxigenic Escherichia coli; Challenge; Clinical trial; COLONIZATION FACTOR ANTIGEN; IRRITABLE-BOWEL-SYNDROME; HEAT-STABLE ENTEROTOXIN; STATES MILITARY PERSONNEL; TRAVELERS DIARRHEA; BISMUTH SUBSALICYLATE; DOUBLE-BLIND; TRIMETHOPRIM-SULFAMETHOXAZOLE; CLINICAL-FEATURES; MOLECULAR CHARACTERIZATION;
D O I
10.1016/j.vaccine.2011.05.021
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Volunteer challenge with enterotoxigenic Escherichia coli (ETEC) has been used for four decades to elucidate the pathogenesis and immune responses and assess efficacy of various interventions. We performed a systematic review of these studies and a meta-analysis of individual patient-level data (IPD) from a subset of studies using standard methodology. We identified 27 studies of 11 ETEC strains administered to 443 naive subjects at doses from 1 x 10(6) to 1 x 10(10) colony forming units (cfu). Diarrhea attack rates varied by strain, dose and enterotoxin. Similar rates were seen at doses of 5 x 10(8) to 1 x 10(10) cfu with the three most commonly used strains B7A, E24377A, H10407. In IPD analysis, the highest diarrhea attack rates were seen with strains B7A, H10407 and E24377A. The H10407 induced significantly higher stool output than the other strains. Additionally, the rate of output was different across strains. The risk of diarrhea, abdominal cramps, nausea and headaches differed significantly by ETEC strain. An increased risk of nausea, abdominal cramps and headaches was seen for females. Baseline anti-LT IgG titers appeared to be associated with a decrease risk of diarrhea outcomes, a trend not seen with anti-LT IgA or seen consistently with anti-colonization factor antibodies. Neither early antibiotic treatment nor diarrhea duration significantly affected the frequency or magnitude of serologic responses. These studies have served as an invaluable tool in understanding disease course, pathogenicity, innate immune responses and an early assessment of product efficacy. When designing and planning experimental ETEC infection studies in this age of increased ethical scrutiny and growing appreciation of post-infectious sequelae, better understanding of available data is essential. Published by Elsevier Ltd.
引用
收藏
页码:5869 / 5885
页数:17
相关论文
共 77 条
[1]   Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease [J].
Alberto, Luis ;
Rodriguez, Garcia ;
Ruigomez, Ana ;
Panes, Julian .
GASTROENTEROLOGY, 2006, 130 (06) :1588-1594
[2]  
[Anonymous], INT PROV UPD CLIN TR
[3]  
[Anonymous], SYSTEMATIC REV HLTH
[4]  
BLACK RE, 1982, REV INFECT DIS, V4, P540
[5]   Enterotoxigenic Escherichia coli with STh and STp genotypes is associated with diarrhea both in children in areas of endemicity and in travelers [J].
Bolin, Ingrid ;
Wiklund, Gudrun ;
Qadri, Firdausi ;
Torres, Olga ;
Bourgeois, A. Louis ;
Savarino, Stephen ;
Svennerhohn, Ann-Mari .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (11) :3872-3877
[6]  
*CDC, 1976, MMWR-MORBID MORTAL W, V25, P229
[7]   LACTOBACILLUS PROPHYLAXIS FOR DIARRHEA DUE TO ENTERO-TOXIGENIC ESCHERICHIA-COLI [J].
CLEMENTS, ML ;
LEVINE, MM ;
BLACK, RE ;
ROBINSBROWNE, RM ;
CISNEROS, LA ;
DRUSANO, GL ;
LANATA, CF ;
SAAH, AJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1981, 20 (01) :104-108
[8]   Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli [J].
Coster, T. S. ;
Wolf, M. K. ;
Hall, E. R. ;
Cassels, F. J. ;
Taylor, D. N. ;
Liu, C. T. ;
Trespalacios, F. C. ;
DeLorimier, A. ;
Angleberger, D. R. ;
McQueen, C. E. .
INFECTION AND IMMUNITY, 2007, 75 (01) :252-259
[9]  
CRYZ SJ, 1995, DEV BIOL STAND, V84, P237
[10]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188